Tacrolimus

Ruzicka, Thomas; Assmann, Till; Homey, Bernhard

doi:10.1001/archderm.135.5.574

Cited by 156 publications

(17 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tacrolimus, also known as (FK506), is a macrolide produced from the fermentation broth of a Japanese soil sample that contained the bacteria Streptomyces tsukubaensis [2]. The generic name is a neologism composed of “Tsukuba macrolide immunosuppressive” [3]. It was among the first macrolide immunosuppressants discovered and was found to have potent in vitro immunosuppressive effects [1].…”

Section: Introductionmentioning

confidence: 99%

Topical tacrolimus in anterior segment inflammatory disorders

Shoughy

2017

Eye and Vis

View full text Add to dashboard Cite

Immune mediated inflammatory anterior segment diseases are variable and their management requires intense immunosuppression. Treatment with topical steroids is associated with serious ocular side effects. In order to overcome the potentially blinding complications of topical steroids, immunomodulatory drugs are being used more frequently. Tacrolimus is a calcineurin inhibitor that induces suppression of T lymphocytes activity and reduction of ocular inflammation. Tacrolimus was recently investigated for application in various anterior segment inflammatory disorders. In this review, we will discuss the therapeutic application of topical tacrolimus as a steroid-sparing agent in treating T cell mediated anterior segment inflammation.

show abstract

Section: Introductionmentioning

confidence: 99%

Topical tacrolimus in anterior segment inflammatory disorders

Shoughy

2017

Eye and Vis

View full text Add to dashboard Cite

show abstract

“…Its immunomodulatory and immunosuppressive activity depends on its effect on calcineurin that ultimately results in the inhibition of the transcription of several cytokine genes under the control of nuclear factor of activated T cells (reviewed in Ruzicka et al [10]). Furthermore, tacrolimus also has an inhibitory action on mast cells and eosinophils by affecting the release of vasoactive peptides and chemokines [10]. Tacrolimus is mainly used for the prevention of allograft rejection [10].…”

Section: Discussionmentioning

confidence: 99%

“…Furthermore, tacrolimus also has an inhibitory action on mast cells and eosinophils by affecting the release of vasoactive peptides and chemokines [10]. Tacrolimus is mainly used for the prevention of allograft rejection [10]. Furthermore, it is increasingly employed in a variety of inflammatory disorders, including asthma, Crohn disease, psoriasis and Behçet disease [10, 11].…”

Section: Discussionmentioning

confidence: 99%

“…Tacrolimus is mainly used for the prevention of allograft rejection [10]. Furthermore, it is increasingly employed in a variety of inflammatory disorders, including asthma, Crohn disease, psoriasis and Behçet disease [10, 11]. Unlike cyclosporine, tacrolimus has been shown to exert potent immunosuppressive action also upon topical application.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Localized Childhood Vulval Pemphigoid Treated with Tacrolimus Ointment

et al. 2004

View full text Add to dashboard Cite

Background: Localized vulval childhood pemphigoid is a rare variant within the pemphigoid group. Although its prognosis seems favorable, the best therapeutic strategy remains unclear. Observation: We here describe the case of an 8-year-old girl presenting with a 5-year history of relapsing vulval pain and lesions suggestive of lichen sclerosus. Clinical features, light microscopy and direct immunofluorescence microscopy were consistent with vulval cicatricial pemphigoid, although the autoantigen(s) involved could not be characterized. Her disease responded to treatment with topical tacrolimus ointment 0.1% within 3 months without any evidence for disease activity, except for slight residual scarring. After 12 months, her treatment was stopped without relapse. Conclusion: This observation suggests that in this rare immune-mediated blistering disease topical tacrolimus is an interesting therapeutic option without the adverse effects associated with topical steroids.

show abstract

“…These two immunosuppressants downmodulate both Th1 and Th2 cells by inhibiting the transcription of various proinflammatory cytokine genes. Since even topical application exerts excellent therapeutic efficacy (11–13), suppression of both Th2 and Th1 cells seems to be a more powerful therapeutic strategy for the treatment of AD, than only Th2 suppression. Yet, in some AD patients, the serum IFN‐γ levels were unexpectedly increased during cyclosporin A therapy, which – intriguingly – was correlated with clinical improvement of AD lesions (35).…”

Section: Viewpointmentioning

confidence: 99%

What are the most promising strategies for the therapeutic immunomodulation of allergic diseases?^Note

Tokura¹,

Röcken²,

Clark³

et al. 2001

Experimental Dermatology

View full text Add to dashboard Cite

Specific immunotherapy and other immunomodulatory strategies have long been a stronghold in the management of allergic diseases. In particular, ''immunodeviation-therapy'' or ''vaccination for allergies'', i.e. the redirection of Th2-type immune responses towards a Th1-response pattern, has become an ever more popular concept. The present feature of CONTROVERSIES complements our previous discussion of atopy (Röcken et al., Exp Dermatol 7: 97-104, 1998), and is dedicated to a critical analysis of the general problems and limitations one faces Viewpoint 1This Viewpoint essay will focus on discussing the validity of several established or currently explored therapies for atopic dermatitis (AD) in the light of our current understanding of the role for T cells in the development of skin lesions of AD.The mechanism underlying atopic dermatitis (AD) involves complex interactions between various cells and cytokines. Cell-mediated responses are performed by T cells, Langerhans cells, mast cells, eosinophils, and monocytes/macrophages. In initial allergic reactions, the majority of pathogenetic T cells are T helper type 2 (Th2) cells producing interleukin (IL)-4, IL-5, and IL-13 but not IFN-g or IL-2. These cytokines regulate IgE synthesis, promote eosinophil differentiation and survival, and induce vascular endothelial adhesion 128 with the main immunomodulatory strategies traditionally considered in this context. We also explore alternative approaches that appear promising in order to achieve both a more effective and/or a more specific immunotherapy of allergic diseases. Given that the mast cell remains a key protagonist in the pathogenesis of allergic diseases finally, this feature examines how innovative, more selectively mast celltargeted strategies may be developed for the management of allergic diseases.

show abstract

Tacrolimus

Cited by 156 publications

References 60 publications

Topical tacrolimus in anterior segment inflammatory disorders

Topical tacrolimus in anterior segment inflammatory disorders

Localized Childhood Vulval Pemphigoid Treated with Tacrolimus Ointment

What are the most promising strategies for the therapeutic immunomodulation of allergic diseases?^Note

Contact Info

Product

Resources

About

Tacrolimus

Cited by 156 publications

References 60 publications

Topical tacrolimus in anterior segment inflammatory disorders

Topical tacrolimus in anterior segment inflammatory disorders

Localized Childhood Vulval Pemphigoid Treated with Tacrolimus Ointment

What are the most promising strategies for the therapeutic immunomodulation of allergic diseases?Note

Contact Info

Product

Resources

About

What are the most promising strategies for the therapeutic immunomodulation of allergic diseases?^Note